BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-08-11 pm EDT
259.40 USD   +0.32%
04:50pBECTON DICKINSON AND : Statement of Changes in Beneficial Ownership - Form 4
PU
08/09BECTON DICKINSON & CO : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/09Becton, Dickinson and Company, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients with Treatments
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wells Fargo Upgrades Becton Dickinson and Co. to Overweight From Equalweight; Price Target is $275

06/24/2022 | 05:02am EDT


© MT Newswires 2022
All news about BECTON, DICKINSON AND COMPANY
04:50pBECTON DICKINSON AND : Statement of Changes in Beneficial Ownership - Form 4
PU
08/09BECTON DICKINSON & CO : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/09Becton, Dickinson and Company, Labcorp Collaborate to Develop Flow Cytometry-Based Comp..
CI
08/08BECTON DICKINSON AND : Announces Tender Offers for Outstanding Debt Securities - Form 8-K
PU
08/08BECTON DICKINSON & CO : Other Events (form 8-K)
AQ
08/08BD Announces Tender Offers for Outstanding Debt Securities
PR
08/08BECTON, DICKINSON AND COMPANY : SEC Filing 8K
CO
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04TRANSCRIPT : Becton, Dickinson and Company, Q3 2022 Earnings Call, Aug 04, 2022
CI
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 822 M - -
Net income 2022 1 866 M - -
Net Debt 2022 13 567 M - -
P/E ratio 2022 37,9x
Yield 2022 1,46%
Capitalization 73 980 M 73 980 M -
EV / Sales 2022 4,65x
EV / Sales 2023 4,44x
Nbr of Employees 75 000
Free-Float 77,6%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 259,40 $
Average target price 274,67 $
Spread / Average Target 5,89%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY5.55%73 740
ABBOTT LABORATORIES-21.65%193 107
MEDTRONIC PLC-10.00%125 125
HOYA CORPORATION-17.18%38 570
SARTORIUS STEDIM BIOTECH-22.10%35 856
DEXCOM, INC.-33.16%35 226